Ausgabe 2/2015
The Spectrum of Motor Neuron Diseases: From Childhood SMA to Adult ALS
Inhalt (22 Artikel)
The Spectrum of Motor Neuron Diseases: From Childhood Spinal Muscular Atrophy to Adult Amyotrophic Lateral Sclerosis
Stacey A. Sakowski, Eva L. Feldman
The Genetics of Spinal Muscular Atrophy: Progress and Challenges
Michelle A. Farrar, Matthew C. Kiernan
Spinal Muscular Atrophy Therapeutics: Where do we Stand?
Constantin d’Ydewalle, Charlotte J. Sumner
Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease
Jeffrey Rosenfeld, Michael J. Strong
The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis
Johnathan Cooper-Knock, Janine Kirby, Robin Highley, Pamela J. Shaw
Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis
Sami J. Barmada
TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets
Emma L. Scotter, Han-Jou Chen, Christopher E. Shaw
Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis
Kristopher G. Hooten, David R. Beers, Weihua Zhao, Stanley H. Appel
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?
Katharine A. Nicholson, Merit E. Cudkowicz, James D. Berry
Neuroimaging as a New Diagnostic Modality in Amyotrophic Lateral Sclerosis
Esther Verstraete, Bradley R. Foerster
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?
Neta Zach, David L. Ennist, Albert A. Taylor, Hagit Alon, Alexander Sherman, Robert Kueffner, Jason Walker, Ervin Sinani, Igor Katsovskiy, Merit Cudkowicz, Melanie L. Leitner
Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis
Stephen A. Goutman, Kevin S. Chen, Eva L. Feldman
Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (“Neuroprotection”)
Heinz Wiendl, Christian Elger, Hans Förstl, Hans-Peter Hartung, Wolfgang Oertel, Heinz Reichmann, Stefan Schwab
A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis
Donald B. Sanders, Jeffrey Rosenfeld, Mazen M. Dimachkie, Lisa Meng, Fady I. Malik
Regulation of Intracellular Copper by Induction of Endogenous Metallothioneins Improves the Disease Course in a Mouse Model of Amyotrophic Lateral Sclerosis
Eiichi Tokuda, Shunsuke Watanabe, Eriko Okawa, Shin-ichi Ono
Rescue of Methyl-CpG Binding Protein 2 Dysfunction-induced Defects in Newborn Neurons by Pentobarbital
Dongliang Ma, Su-In Yoon, Chih-Hao Yang, Guillaume Marcy, Na Zhao, Wan-Ying Leong, Vinu Ganapathy, Ju Han, Antonius M. J. Van Dongen, Kuei-Sen Hsu, Guo-Li Ming, George J. Augustine, Eyleen L. K. Goh
Diffusion Efficiency and Bioavailability of Resveratrol Administered to Rat Brain by Different Routes: Therapeutic Implications
Xiao-Hong Shu, Li-Li Wang, Hong Li, Xue Song, Shun Shi, Jia-Yao Gu, Mo-Li Wu, Xiao-Yan Chen, Qing-You Kong, Jia Liu
Enhanced Retinal Ganglion Cell Survival in Glaucoma by Hypoxic Postconditioning After Disease Onset
Jeffrey M. Gidday, Lihong Zhang, Chia-Wen Chiang, Yanli Zhu
Erratum to: TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets
Emma L. Scotter, Han-Jou Chen, Christopher E. Shaw